STRATEGIES TO IMPROVE OUTCOMES FOR TNBC PATIENTS INTEGRATING SUBTYPE-SPECIFIC GENOMIC AND IMMUNE-BASED DISCOVERIES Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, representing ~25% of all breast cancer deaths due to lack of effective therapies. To address this challenge, our team integrated expertise in molecular genetics, oncology and bioinformatics, and 1) classified TNBC into distinct molecular subtypes with unique signaling, biologic and immune features, and 2) discovered and validated novel gene rearrangements in oncogenic and immune-regulatory genes that provide a diverse array of mechanisms by which TNBC tumors evade immune surveillance. Many tumor cells co-opt innate and adaptive immune system mechanisms through direct upregulation of PD-L1 or through recruitment of immune suppressive cells. These forms of immune evasion are in play for tumors with high gene mutation burdens, such as select TNBC subtypes. In the current period, we discovered that some TNBC tumors with high mutation loads remain ?immune cold? due to absence of immune cells in the tumor and enrichment of immune suppressive cells in the microenvironment. Immunotherapies targeting the PD-1/PD-L1 pathway continue to be a paradigm shift in the treatment of metastatic cancers with high mutation rates, thus it is critical to understand how to align appropriate TNBC patients with this therapeutic advance. As combination chemo-immunotherapy advances toward FDA approval for metastatic TNBC, it further catalyzes the need to understand how specific chemotherapeutic agents can enhance TNBC subtype-specific response to anti-PD-1/PD-L1 therapy in order to determine the most efficacious combinations. The mechanisms by which chemotherapy modulates neoantigen burden, T-cell function, and immune-suppressive cell function in TNBC are largely unknown. We propose to test the interrelated hypotheses that: (1) standard chemotherapies modulate tumor immune response targeted by anti-PD-L1 therapy in a TNBC-subtype specific manner; and (2) subtype-specific TNBC preclinical models will provide insights to chemotherapy-specific systemic and tumor microenvironment mechanisms of immune suppression. The project's Specific Aims are:
Aim 1 : To determine mechanisms by which standard chemotherapies modulate tumor immune response in combination with checkpoint immunotherapy;
Aim 2 : To determine mechanisms by which by tumor secreted proteins and exosomes modulate the immune system in metastatic TNBC subtypes;
and Aim 3 : To evaluate the feasibility of targeting the tumor microenvironment myeloid-derived cells. IMPACT: Our overall goal is improved outcomes for TNBC patients through alignment of combination therapy directed by knowledge of TNBC subtypes and immunomodulatory features. Through the comprehensive analysis of biospecimens, our established multi- disciplinary team will develop biomarkers for PD-L1 response and define the effects of chemotherapy on distinct immune cell populations. The discovery of new immune-evasion mechanisms will lead to actionable molecular targets for future drug discovery efforts impacting metastatic TNBC and other breast cancers.

Public Health Relevance

PROJECT 2: STRATEGIES TO IMPROVE OUTCOMES FOR TNBC PATIENTS INTEGRATING SUBTYPE- SPECIFIC GENOMIC AND IMMUNE-BASED DISCOVERIES NARRATIVE Triple-negative breast cancer (TNBC) affects younger women, accounting for 25% of all breast cancer deaths due to more frequent metastasis and shorter survival outcomes when compared to other breast cancer subtypes. Metastatic TNBC is especially lethal, with the majority of patients surviving less than 18 months. Using our discovery framework of preclinical models, genomic tools, TNBC biospecimens, and a clinical trial in metastatic disease, we will identify biomarkers of response to chemoimmunotherapy, and identify pathways of immune-evasion that may represent actionable molecular targets for future drug discovery efforts and/or translational and clinical investigation in TNBC and other cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA098131-17A1
Application #
9791055
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
17
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Santos Guasch, Gabriela L; Beeler, J Scott; Marshall, Clayton B et al. (2018) p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. iScience 8:236-249
Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435
Elion, David L; Cook, Rebecca S (2018) Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. Oncotarget 9:29007-29017
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194
Luo, Na; Nixon, Mellissa J; Gonzalez-Ericsson, Paula I et al. (2018) DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 9:248
Sudhan, Dhivya R; Schwarz, Luis J; Guerrero-Zotano, Angel et al. (2018) Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clin Cancer Res :
Werfel, Thomas A; Wang, Shan; Jackson, Meredith A et al. (2018) Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res 78:1845-1858
Zhao, Shilin; Li, Chung-I; Guo, Yan et al. (2018) RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics 19:191
Edwards, Deanna N; Ngwa, Verra M; Wang, Shan et al. (2017) The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ. Sci Signal 10:

Showing the most recent 10 out of 341 publications